Implications of Global Pricing Policies on Access to Innovative Drugs: The Case of Trastuzumab in Seven Latin American Countries

Abstract

Although CE in other settings, trastuzumab was not CE in LA. The use of health technology assessment to prioritize resource allocation and support price negotiations is critical to making innovative drugs available and affordable in developing countries.

Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission

“…These unsatisfactory outcomes may be due to limited access to expensive drugs (49)(50)(51)(52)(53). In this cohort, only 16% of the patients were able to receive bortezomib and none received lenalidomide.…”

Enhancing global access to cancer medicines

“…It would also allow other cancer medicines to be considered for inclusion on the World Health Organization Model Lists of Essential Medicines. Table describes some methods to help reduce cancer medicine prices …”

Defining a Health Benefits Package: What Are the Necessary Processes?

“…Managing and implementing HBP: Once resources are allocated, there is an ongoing process of HBP services implementation via payers and providers doing care delivery. But in the context of the HBP framing, we use management and implementation of the HBP to denote the tasks that the HBP manager must carry out to continuously update and monitor HBP payment and services using prescription and utilization data, communicate with stakeholder groups on included and excluded services, resolve disputes, manage exclusions, inform price negotiations with manufacturers (see Yothasamut et al 32 and Pichon-Riviere et al 33 ), prepare financial forecasts and plan needed adjustments, and so on. In essence, implementing the HBP means assuring that it is delivered in practice, in line with the goals that were initially set out, and both financially and institutionally sustainable.…”